The Effect of Different β-Blockers on Vascular Graft Nitric Oxide Levels: Comparison of Nebivolol...
1
Catheter-directed Foam Sclerotherapy of Great Saphenous Veins in Combination with Pre-treatment Reduction of the Diameter Employing the Principals of Perivenous Tumescent Local Anesthesia Devereux N., Recke A.L., Westermann L., Recke A., Kahle B. Eur J Vasc Endovasc Surg 2014;47:186-94. Objectives: The aim of this study was to evaluate occlusion rates of great saphenous veins (GSV) with a diameter between 5-10 mm that received a pre-treatment size reduction via perivenous tumescent application (TA) followed by catheter-directed foam sclerotherapy (CDFS). Methods: A prospective blinded randomized clinical trial comparing the occlusion rates of GSV at 1-, 6-, and 12-month follow-up. Fifty pa- tients were included and randomized into two groups. CDFS was per- formed accessing the GSV at knee level and applying 8 mL of 2% polidocanol-foam (EasyFoam) while the catheter was withdrawn. Strictly perivenous TA was performed in group 1 before applying the sclerosant agent. Occlusion rates and clinical scores were assessed by blinded examiners. Results: After 12 months in group 1 full occlusion was achieved in 73.9%, partial occlusion in 8.7%, and 17.4% were classified as treatment fail- ure. In group 2, 75% of the targeted GSV were fully occluded, 20% were partially occluded, and 5% were diagnosed as treatment failure. Both groups showed a significant reduction of the vein diameter. Patient's tolerance and satisfaction with the treatment was high in both groups. Conclusion: No benefit could be found using additional TA to reduce the vein diameter before the treatment. The Effect of Different b-Blockers on Vascular Graft Nitric Oxide Levels: Comparison of Nebivolol Versus Metoprolol Bayar E., Ilhan G., Furat C., Atik C., Arslanoglu Y., Kuran C., Ozpak B., Durakoglugil M.E. Eur J Vasc Endovasc Surg 2014;47:203-7. Objectives: The aim of this study was to investigate the effects of the vasodilating b-blocker nebivolol and the cardioselective b-blocker metopro- lol on nitric oxide (NO) levels at vascular graft endothelium and vasa vaso- rum compared to controls in patients undergoing coronary artery bypass graft surgery. Methods: This was a prospective study. Fifty-five patients were divided into three groups: nebivolol group (group N, n ¼ 23), metoprolol group (group M, n ¼ 16), and control group (group A, n ¼ 16). Group N received nebivolol 5 mg once daily, and group M received metoprolol 50 mg once daily for 15 days in the preoperative period. Control patients did not use b-blocker therapy. Tissue samples of both left internal mammary ar- tery (LIMA) and saphenous vein grafts were investigated for NO activity us- ing immunohistochemical methods. Results: Demographic characteristics and risk factors were similar be- tween groups. We observed the highest NO activity in group N in both endothelial and vasa vasorum samples of LIMA and saphenous veins. NO activity of metoprolol group was similar to controls. Conclusions: According to our results, we think that nebivolol may be safer and preferable in order to diminish graft spasm in patients undergo- ing coronary artery bypass graft surgery due to the NO-mediated vasodilat- ing effect. JOURNAL OF VASCULAR SURGERY Volume 59, Number 2 Abstracts 557
Transcript of The Effect of Different β-Blockers on Vascular Graft Nitric Oxide Levels: Comparison of Nebivolol...
JOURNAL OF VASCULAR SURGERYVolume 59, Number 2 Abstracts 557
Catheter-directed Foam Sclerotherapy of Great Saphenous Veins inCombination with Pre-treatment Reduction of the DiameterEmploying the Principals of Perivenous Tumescent Local AnesthesiaDevereux N., Recke A.L., Westermann L., Recke A., Kahle B. Eur J VascEndovasc Surg 2014;47:186-94.
Objectives: The aim of this study was to evaluate occlusion rates ofgreat saphenous veins (GSV) with a diameter between 5-10 mm thatreceived a pre-treatment size reduction via perivenous tumescent application(TA) followed by catheter-directed foam sclerotherapy (CDFS).
Methods: A prospective blinded randomized clinical trial comparingthe occlusion rates of GSV at 1-, 6-, and 12-month follow-up. Fifty pa-tients were included and randomized into two groups. CDFS was per-formed accessing the GSV at knee level and applying 8 mL of 2%polidocanol-foam (EasyFoam) while the catheter was withdrawn. Strictlyperivenous TA was performed in group 1 before applying the sclerosantagent. Occlusion rates and clinical scores were assessed by blindedexaminers.
Results: After 12 months in group 1 full occlusion was achieved in73.9%, partial occlusion in 8.7%, and 17.4% were classified as treatment fail-ure. In group 2, 75% of the targeted GSV were fully occluded, 20% werepartially occluded, and 5% were diagnosed as treatment failure. Both groupsshowed a significant reduction of the vein diameter. Patient's tolerance andsatisfaction with the treatment was high in both groups.
Conclusion: No benefit could be found using additional TA toreduce the vein diameter before the treatment.
The Effect of Different b-Blockers on Vascular Graft Nitric OxideLevels: Comparison of Nebivolol Versus MetoprololBayar E., Ilhan G., Furat C., Atik C., Arslanoglu Y., Kuran C., Ozpak B.,Durakoglugil M.E. Eur J Vasc Endovasc Surg 2014;47:203-7.
Objectives: The aim of this study was to investigate the effects of thevasodilating b-blocker nebivolol and the cardioselective b-blocker metopro-lol on nitric oxide (NO) levels at vascular graft endothelium and vasa vaso-rum compared to controls in patients undergoing coronary artery bypassgraft surgery.
Methods: This was a prospective study. Fifty-five patients weredivided into three groups: nebivolol group (group N, n ¼ 23), metoprololgroup (group M, n ¼ 16), and control group (group A, n ¼ 16). Group Nreceived nebivolol 5 mg once daily, and group M received metoprolol 50mg once daily for 15 days in the preoperative period. Control patients didnot use b-blocker therapy. Tissue samples of both left internal mammary ar-tery (LIMA) and saphenous vein grafts were investigated for NO activity us-ing immunohistochemical methods.
Results: Demographic characteristics and risk factors were similar be-tween groups. We observed the highest NO activity in group N in bothendothelial and vasa vasorum samples of LIMA and saphenous veins. NOactivity of metoprolol group was similar to controls.
Conclusions: According to our results, we think that nebivolol maybe safer and preferable in order to diminish graft spasm in patients undergo-ing coronary artery bypass graft surgery due to the NO-mediated vasodilat-ing effect.
